Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Public ClinicalTrials.gov record NCT01643499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Study identification
- NCT ID
- NCT01643499
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- University of Chicago
- Other
- Enrollment
- 79 participants
Conditions and interventions
Conditions
- Acinar Cell Adenocarcinoma of the Pancreas
- Adenocarcinoma of Unknown Primary
- Adenocarcinoma of the Gallbladder
- Adult Primary Cholangiocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Cholangiocarcinoma of the Gallbladder
- Diffuse Adenocarcinoma of the Stomach
- Duct Cell Adenocarcinoma of the Pancreas
- Intestinal Adenocarcinoma of the Stomach
- Localized Unresectable Adult Primary Liver Cancer
- Metastatic Carcinoma of Unknown Primary
- Metastatic Extrahepatic Bile Duct Cancer
- Mixed Adenocarcinoma of the Stomach
- Mucinous Adenocarcinoma of the Colon
- Mucinous Adenocarcinoma of the Rectum
- Newly Diagnosed Carcinoma of Unknown Primary
- Signet Ring Adenocarcinoma of the Colon
- Signet Ring Adenocarcinoma of the Rectum
- Stage III Pancreatic Cancer
- Stage IIIA Colon Cancer
- Stage IIIA Gallbladder Cancer
- Stage IIIA Gastric Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Gallbladder Cancer
- Stage IIIB Gastric Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Gastric Cancer
- Stage IIIC Rectal Cancer
- Stage IV Gastric Cancer
- Stage IV Pancreatic Cancer
- Stage IVA Colon Cancer
- Stage IVA Gallbladder Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Gallbladder Cancer
- Stage IVB Rectal Cancer
- Unresectable Extrahepatic Bile Duct Cancer
Interventions
- fluorouracil Drug
- irinotecan hydrochloride Drug
- laboratory biomarker analysis Other
- leucovorin calcium Drug
- oxaliplatin Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2012
- Primary completion
- Aug 27, 2016
- Completion
- Jun 30, 2019
- Last update posted
- May 7, 2020
2012 – 2019
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637-1470 | — |
| Evanston CCOP-NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01643499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2020 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01643499 live on ClinicalTrials.gov.